{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Opdivo&page=6",
    "query": {
      "intervention": "Opdivo",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 1207,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Opdivo&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Opdivo&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T21:22:23.475Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01822509",
      "title": "Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplant Recipient",
        "Myeloproliferative Neoplasm",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Recurrent Hematologic Malignancy",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Myelodysplastic Syndrome",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2013-05-16",
      "completion_date": "2021-06-10",
      "has_results": false,
      "last_update_posted_date": "2021-06-24",
      "last_synced_at": "2026-10-18T21:22:23.475Z",
      "location_count": 13,
      "location_summary": "Duarte, California • La Jolla, California • South Pasadena, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01822509"
    },
    {
      "nct_id": "NCT05611229",
      "title": "Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib+Trametinib",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Ipilimumab+Nivolumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Vemurafenib+Cobimetinib",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Encorafenib+Binimetinib",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1975,
      "start_date": "2020-06-16",
      "completion_date": "2021-12-03",
      "has_results": false,
      "last_update_posted_date": "2023-04-06",
      "last_synced_at": "2026-10-18T21:22:23.475Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05611229"
    },
    {
      "nct_id": "NCT06630429",
      "title": "A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Renal Cell Carcinoma (RCC)"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-09-02",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-18T21:22:23.475Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630429"
    },
    {
      "nct_id": "NCT02498600",
      "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2015-08-10",
      "completion_date": "2025-07-26",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-10-18T21:22:23.475Z",
      "location_count": 201,
      "location_summary": "Auburn, California • Berkeley, California • Cameron Park, California + 140 more",
      "locations": [
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Cameron Park",
          "state": "California"
        },
        {
          "city": "Davis",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02498600"
    },
    {
      "nct_id": "NCT03523572",
      "title": "Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2018-08-02",
      "completion_date": "2023-09-12",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-10-18T21:22:23.475Z",
      "location_count": 10,
      "location_summary": "Santa Monica, California • New Haven, Connecticut • Miami, Florida + 7 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03523572"
    },
    {
      "nct_id": "NCT04730349",
      "title": "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ependymoma",
        "Ewing Sarcoma",
        "High-grade Glioma",
        "Leukemia and Lymphoma",
        "Medulloblastoma",
        "Miscellaneous Brain Tumors",
        "Miscellaneous Solid Tumors",
        "Neuroblastoma",
        "Relapsed, Refractory Malignant Neoplasms",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NKTR-214",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 15,
      "start_date": "2021-06-03",
      "completion_date": "2022-06-22",
      "has_results": true,
      "last_update_posted_date": "2023-03-24",
      "last_synced_at": "2026-10-18T21:22:23.475Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas • St Louis, Missouri",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04730349"
    },
    {
      "nct_id": "NCT03825510",
      "title": "Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Nonsmall Cell Lung Cancer",
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Stereotactic Body Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Crozer-Keystone Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-04-28",
      "completion_date": "2022-03-08",
      "has_results": false,
      "last_update_posted_date": "2023-03-06",
      "last_synced_at": "2026-10-18T21:22:23.475Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03825510"
    },
    {
      "nct_id": "NCT03873402",
      "title": "A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 437,
      "start_date": "2019-06-21",
      "completion_date": "2027-03-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-18T21:22:23.475Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Athens, Georgia • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03873402"
    },
    {
      "nct_id": "NCT05041062",
      "title": "A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Peritoneal Mesothelioma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-12-01",
      "completion_date": "2023-04-13",
      "has_results": true,
      "last_update_posted_date": "2024-01-03",
      "last_synced_at": "2026-10-18T21:22:23.475Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05041062"
    },
    {
      "nct_id": "NCT04624178",
      "title": "A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-11-05",
      "completion_date": "2026-11-16",
      "has_results": true,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-10-18T21:22:23.475Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04624178"
    }
  ]
}